Doxorubicin HCL

Phase 2Small molecule

MMemorial Sloan Kettering Cancer Center

Doxorubicin HCL is one of 54 small molecule programs targeting Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Epithelioid SarcomaActive, not recruiting

Breast CancerActive, not recruiting

LymphomaPreclinical

Active, not recruiting

Epithelioid SarcomaPhase 1

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

Doxorubicin HCL

MMemorial Sloan Kettering Cancer Center

Phase 2

1 3

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 4

Chantix

PPrism Pharmaceuticals

Preclinical

1 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

Vfend

PPrism Pharmaceuticals

Preclinical

—7

Fentanyl Citrate

IINSYS Therapeutics Inc

Preclinical

2 8

Motexafin Gadolinium

PPharmacyclics LLC.

Preclinical

1 9

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

1 10

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Breast Cancer1 trial

QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine

Withdrawn·IImmunityBio, Inc.·Phase 2·NCT03554109

Epithelioid Sarcoma1 trial

Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma

Terminated·EEpizyme, Inc.·Phase 1·NCT04204941·25 enrolled

Lymphoma1 trial

Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·N/A·NCT01868451·118 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Doxorubicin HCL. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Doxorubicin HCL compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Doxorubicin HCL. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Memorial Sloan Kettering Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMemorial Sloan Kettering Cancer Center

Doxorubicin HCL

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Breast Cancer1 trial

Epithelioid Sarcoma1 trial

Lymphoma1 trial

References

Drug Info

Quick Facts

Related News